216 related articles for article (PubMed ID: 21266502)
1. Gene expression profiling of skeletal muscles treated with a soluble activin type IIB receptor.
Rahimov F; King OD; Warsing LC; Powell RE; Emerson CP; Kunkel LM; Wagner KR
Physiol Genomics; 2011 Apr; 43(8):398-407. PubMed ID: 21266502
[TBL] [Abstract][Full Text] [Related]
2. Co-Administration of Myostatin-Targeting siRNA and ActRIIB-Fc Fusion Protein Increases Masseter Muscle Mass and Fiber Size.
Bayarsaikhan O; Kawai N; Mori H; Kinouchi N; Nikawa T; Tanaka E
J Nutr Sci Vitaminol (Tokyo); 2017; 63(4):244-248. PubMed ID: 28978871
[TBL] [Abstract][Full Text] [Related]
3. Myostatin, activin receptor IIb, and follistatin-like-3 gene expression are altered in adipose tissue and skeletal muscle of obese mice.
Allen DL; Cleary AS; Speaker KJ; Lindsay SF; Uyenishi J; Reed JM; Madden MC; Mehan RS
Am J Physiol Endocrinol Metab; 2008 May; 294(5):E918-27. PubMed ID: 18334608
[TBL] [Abstract][Full Text] [Related]
4. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
[TBL] [Abstract][Full Text] [Related]
5. Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.
Puolakkainen T; Ma H; Kainulainen H; Pasternack A; Rantalainen T; Ritvos O; Heikinheimo K; Hulmi JJ; Kiviranta R
BMC Musculoskelet Disord; 2017 Jan; 18(1):20. PubMed ID: 28103859
[TBL] [Abstract][Full Text] [Related]
6. Increased muscle force production and bone mineral density in ActRIIB-Fc-treated mature rodents.
Chiu CS; Peekhaus N; Weber H; Adamski S; Murray EM; Zhang HZ; Zhao JZ; Ernst R; Lineberger J; Huang L; Hampton R; Arnold BA; Vitelli S; Hamuro L; Wang WR; Wei N; Dillon GM; Miao J; Alves SE; Glantschnig H; Wang F; Wilkinson HA
J Gerontol A Biol Sci Med Sci; 2013 Oct; 68(10):1181-92. PubMed ID: 23525481
[TBL] [Abstract][Full Text] [Related]
7. A myostatin and activin decoy receptor enhances bone formation in mice.
Bialek P; Parkington J; Li X; Gavin D; Wallace C; Zhang J; Root A; Yan G; Warner L; Seeherman HJ; Yaworsky PJ
Bone; 2014 Mar; 60():162-71. PubMed ID: 24333131
[TBL] [Abstract][Full Text] [Related]
8. The effects of an ActRIIb receptor Fc fusion protein ligand trap in juvenile simian immunodeficiency virus-infected rhesus macaques.
O'Connell KE; Guo W; Serra C; Beck M; Wachtman L; Hoggatt A; Xia D; Pearson C; Knight H; O'Connell M; Miller AD; Westmoreland SV; Bhasin S
FASEB J; 2015 Apr; 29(4):1165-75. PubMed ID: 25466897
[TBL] [Abstract][Full Text] [Related]
9. ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders.
Li J; Fredericks M; Cannell M; Wang K; Sako D; Maguire MC; Grenha R; Liharska K; Krishnan L; Bloom T; Belcheva EP; Martinez PA; Castonguay R; Keates S; Alexander MJ; Choi H; Grinberg AV; Pearsall RS; Oh P; Kumar R; Suragani RN
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586684
[TBL] [Abstract][Full Text] [Related]
10. Dystrophin-deficient dogs with reduced myostatin have unequal muscle growth and greater joint contractures.
Kornegay JN; Bogan DJ; Bogan JR; Dow JL; Wang J; Fan Z; Liu N; Warsing LC; Grange RW; Ahn M; Balog-Alvarez CJ; Cotten SW; Willis MS; Brinkmeyer-Langford C; Zhu H; Palandra J; Morris CA; Styner MA; Wagner KR
Skelet Muscle; 2016; 6():14. PubMed ID: 27047655
[TBL] [Abstract][Full Text] [Related]
11. Elevated expression of activins promotes muscle wasting and cachexia.
Chen JL; Walton KL; Winbanks CE; Murphy KT; Thomson RE; Makanji Y; Qian H; Lynch GS; Harrison CA; Gregorevic P
FASEB J; 2014 Apr; 28(4):1711-23. PubMed ID: 24378873
[TBL] [Abstract][Full Text] [Related]
12. The role of myostatin and activin receptor IIB in the regulation of unloading-induced myofiber type-specific skeletal muscle atrophy.
Babcock LW; Knoblauch M; Clarke MS
J Appl Physiol (1985); 2015 Sep; 119(6):633-42. PubMed ID: 26205544
[TBL] [Abstract][Full Text] [Related]
13. Myostatin/activin blocking combined with exercise reconditions skeletal muscle expression profile of mdx mice.
Kainulainen H; Papaioannou KG; Silvennoinen M; Autio R; Saarela J; Oliveira BM; Nyqvist M; Pasternack A; 't Hoen PA; Kujala UM; Ritvos O; Hulmi JJ
Mol Cell Endocrinol; 2015 Jan; 399():131-42. PubMed ID: 25304272
[TBL] [Abstract][Full Text] [Related]
14. A novel therapeutic approach to treating obesity through modulation of TGFβ signaling.
Koncarevic A; Kajimura S; Cornwall-Brady M; Andreucci A; Pullen A; Sako D; Kumar R; Grinberg AV; Liharska K; Ucran JA; Howard E; Spiegelman BM; Seehra J; Lachey J
Endocrinology; 2012 Jul; 153(7):3133-46. PubMed ID: 22549226
[TBL] [Abstract][Full Text] [Related]
15. Exercise restores decreased physical activity levels and increases markers of autophagy and oxidative capacity in myostatin/activin-blocked mdx mice.
Hulmi JJ; Oliveira BM; Silvennoinen M; Hoogaars WM; Pasternack A; Kainulainen H; Ritvos O
Am J Physiol Endocrinol Metab; 2013 Jul; 305(2):E171-82. PubMed ID: 23695214
[TBL] [Abstract][Full Text] [Related]
16. Development of novel activin-targeted therapeutics.
Chen JL; Walton KL; Al-Musawi SL; Kelly EK; Qian H; La M; Lu L; Lovrecz G; Ziemann M; Lazarus R; El-Osta A; Gregorevic P; Harrison CA
Mol Ther; 2015 Mar; 23(3):434-44. PubMed ID: 25399825
[TBL] [Abstract][Full Text] [Related]
17. Myostatin deficiency but not anti-myostatin blockade induces marked proteomic changes in mouse skeletal muscle.
Salzler RR; Shah D; Doré A; Bauerlein R; Miloscio L; Latres E; Papadopoulos NJ; Olson WC; MacDonald D; Duan X
Proteomics; 2016 Jul; 16(14):2019-27. PubMed ID: 27214824
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice.
Sumner CJ; Wee CD; Warsing LC; Choe DW; Ng AS; Lutz C; Wagner KR
Hum Mol Genet; 2009 Sep; 18(17):3145-52. PubMed ID: 19477958
[TBL] [Abstract][Full Text] [Related]
19. Administration of a soluble activin type IIB receptor promotes the transplantation of human myoblasts in dystrophic mice.
Fakhfakh R; Lee SJ; Tremblay JP
Cell Transplant; 2012; 21(7):1419-30. PubMed ID: 22449443
[TBL] [Abstract][Full Text] [Related]
20. Activin Receptor Type IIB Inhibition Improves Muscle Phenotype and Function in a Mouse Model of Spinal Muscular Atrophy.
Liu M; Hammers DW; Barton ER; Sweeney HL
PLoS One; 2016; 11(11):e0166803. PubMed ID: 27870893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
